OKYO

OKYO Pharma

OKYO

Market cap $78.6M

Overview Fund Activity

2.09 USD

-0.06

2.79%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

2.10

+0.01

0.48%

1 day

-2.79%

5 days

-5.43%

1 month

-21.13%

3 months

-18.36%

6 months

40.27%

Year to date

84.96%

1 year

99.05%

5 years

-42.27%

10 years

-42.27%

About: OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.

Employees: 4

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

2.07% more ownership

Funds ownership: 6.12% [Q1] → 8.19% (+2.07%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

29% less funds holding

Funds holding: 7 [Q1] → 5 (-2) [Q2]

44% less capital invested

Capital invested by funds: $2.63M [Q1] → $1.48M (-$1.16M) [Q2]

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

See Fund Rankings

Financial journalist opinion

Proactive Investors

OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMI

OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob talked with Proactive about the recently announced topline data from the company's Phase 2 trial evaluating urcosimod in patients with neuropathic corneal pain. Jacob explained that neuropathic corneal pain is a severe nerve pain condition without any FDA-approved treatments, describing it as “like having a spinal cord injury in your eye.

OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMI

Proactive Investors

OKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapy

OKYO Pharma Ltd (NASDAQ:OKYO) announced it has secured $1.9 million in non-dilutive funding to support the development of urcosimod, its lead drug candidate for neuropathic corneal pain (NCP). NCP is a chronic, nerve-related ocular condition that currently has no US Food and Drug (FDA)-approved treatments.

OKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapy

Proactive Investors

OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal pain

OKYO Pharma Ltd (NASDAQ:OKYO) on Wednesday reported promising top-line results from a Phase 2 trial of its investigational drug urcosimod for neuropathic corneal pain (NCP), with 75% of patients showing greater than 80% pain reduction after 12 weeks of treatment. Patients treated with the 0.05% formulation of urcosimod saw a statistically significant reduction in pain scores compared to baseline, as measured by the Visual Analogue Scale (VAS), with an average improvement of 5.5 points versus 2.75 in the placebo group.

OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal pain

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

LONDON and NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, is pleased to announce positive top-line data from the recently closed 18-patient Phase 2 trial of urcosimod (formerly called OK-101) to treat NCP. OKYO is the first company to conduct a clinical study to treat NCP disease, a major unmet medical need.

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

Proactive Investors

OKYO Pharma poised for breakout as Phase 2 trial nears results: analysts

Shares of OKYO Pharma Ltd (NASDAQ:OKYO) have nearly doubled since the start of the year, fueled by a string of clinical and regulatory milestones that may pave the way for a transformative treatment in the underserved field of ocular pain. In a new note research report, Goldman Small Cap Research raised its price target on the stock to $8, up from $5, citing strong momentum, accelerated clinical progress, and growing interest from patients and clinicians alike in the company's lead drug candidate, urcosimod.

OKYO Pharma poised for breakout as Phase 2 trial nears results: analysts

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

Raising Price Target Due to Fundamental Drivers BALTIMORE, MD / ACCESS Newswire / June 11, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research update on OKYO Pharma Limited (NASDAQ:OKYO), an emerging player in the fast-growing ophthalmic drugs segment. The Goldman report carries a price target.

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

Proactive Investors

OKYO Pharma CEO to present drug research for debilitating eye pain at Boston summit

OKYO Pharma Ltd (NASDAQ:OKYO) shares could see renewed attention this week as the company's chief executive, Gary Jacob, is set to present findings on its lead drug candidate at a biotech conference in Boston. Jacob will speak at the GPCRs-Targeted Drug Discovery Summit on May 22, where he'll share the latest data on urcosimod, a treatment in development for neuropathic corneal pain—a chronic eye condition that causes severe discomfort and currently has no approved therapies.

OKYO Pharma CEO to present drug research for debilitating eye pain at Boston summit

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that its CEO, Gary S. Jacob, Ph.D., will be giving an oral presentation at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on May 22, 2025. Dr. Jacob's presentation will cover the development of urcosimod, OKYO's lead clinical drug candidate, to treat neuropathic corneal pain (NCP) which is a debilitating condition affecting many tens of thousands worldwide, and is characterized by chronic, severe eye discomfort.

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

Proactive Investors

OKYO moves toward FDA talks after eye drug trial – ICYMI

OKYO Pharma Ltd (NASDAQ:OKYO) earlier this week announced the early termination of its Phase 2 trial evaluating urcosimod (formerly OK-101) for neuropathic corneal pain. The company said the 48-patient study, which began in October 2024, was initially planned to continue through the end of the year.

OKYO moves toward FDA talks after eye drug trial – ICYMI

Proactive Investors

OKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal pain

OKYO Pharma Ltd (NASDAQ:OKYO) announced that the US Food and Drug Administration has granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain (NCP), a chronic ocular condition with no FDA-approved therapies. The designation is intended to expedite the development and review of drugs targeting serious conditions with unmet medical needs.

OKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal pain

See News Rankings

Charts implemented using Lightweight Charts™